CDKN2A and glioblastoma: Taken together, DNA mutational analysis suggests NF1-mutant and NF1 wild-type tumors exhibit differences in comutation patterns with no global difference in baseline clinical parameters or outcomes, and CDKN2A/B loss is a negative prognostic marker in NF1-mutant but not NF1 wild-type glioblastomas, which underscores the intertumor heterogeneity across NF1-mutant, IDH wild-type glioblastomas.